AngioDynamics, Inc. ANGO · NASDAQ
$12.02 +1.09% (+$0.13)
Summary
29 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $34.0M in cash.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Revenue fell by 1.9% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 1.9% a year over 5 years. Over the last 3 years it fell by 1.9% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $32.9M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $19.5 is 62% above today's price. 45% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Med Device 65%
- Med Tech 35%
By region
- UNITED STATES 86%
- Non-US 14%
Med Device brings in 65% of revenue. Med Tech grew fastest, by 16% a year.
Segments in detail